Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro‐Cardiovascular Events and Neoplasm Development
International Journal of Urology · 2025
DOI: 10.1111/iju.70228 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Tomoko Hamaya und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Cardiovascular Diseases, Neoplasms, Cerebrovascular Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Oyokyo Kidney Reserch Institure.
Abstract (Originalsprache)
Objectives
Reports on the benefits of preemptive kidney transplantation (PEKT) have been conflicting. We assessed postoperative unfavorable outcomes to determine the potential advantages of PEKT.
Methods
We conducted a retrospective multicenter study including 567 living donor kidney transplantation recipients registered in the Michinoku Renal Transplant Network database between June 1998 and June 2021. The recipients were classified into two groups: PEKT and non‐PEKT. We compared overall survival, graft survival, rejection‐free survival, cerebro‐cardiovascular disease (CCVD)‐free survival, neoplasm‐free survival, and a combined endpoint (CCVD and/or neoplasm development) between the two groups. To adjust for baseline heterogeneity, we employed inverse probability of treatment weighting (IPTW).
Results
Of the 567 recipients, 152 (27%) received PEKT and 415 (73%) received non‐PEKT. There were no significant differences in the major outcomes. However, PEKT was significantly associated with a reduced risk of the combined endpoint in both the multivariate Cox regression analysis (hazard ratio [HR]: 0.51, p = 0.029) and the IPTW‐adjusted Cox regression analysis (HR: 0.57, p = 0.019).
Conclusions
PEKT may confer a potential benefit in reducing the risk of CCVD and/or neoplasm development, although its advantages appear limited for other clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Urology, Iwate Medical University, Morioka, Japan.
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
- Department of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
- Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
ORCID-Profile: Tomohiko Matsuura, Hayato Nishida, Hirotake Kodama, Norihiko Tsuchiya, Wataru Obara, Shingo Hatakeyama
Förderung
- Oyokyo Kidney Reserch Institure
Zitieren
APA
Hamaya, T., Matsuura, T., Saito, M., Nishida, H., Maita, S., Murakami, R., Ito, A., Kodama, H., Tomita, H., Saitoh, H., Tsuchiya, N., Habuchi, T., Obara, W., Ohyama, C., & Hatakeyama, S. (2025). Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro‐Cardiovascular Events and Neoplasm Development. International Journal of Urology. https://doi.org/10.1111/iju.70228
Vancouver
Hamaya T, Matsuura T, Saito M, Nishida H, Maita S, Murakami R, et al. Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro‐Cardiovascular Events and Neoplasm Development. International Journal of Urology. 2025. doi:10.1111/iju.70228
BibTeX
@article{Hamaya2025,
author = {Hamaya, Tomoko and Matsuura, Tomohiko and Saito, Mitsuru and Nishida, Hayato and Maita, Shinya and Murakami, Reiichi and Ito, Ayato and Kodama, Hirotake and Tomita, Hirofumi and Saitoh, Hisao and Tsuchiya, Norihiko and Habuchi, Tomonori and Obara, Wataru and Ohyama, Chikara and Hatakeyama, Shingo},
title = {Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro‐Cardiovascular Events and Neoplasm Development},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70228}
}
EUVIMED